Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Central Nervous System (CNS) Embryonal Tumors
- Cellular and Molecular Classification of CNS Embryonal Tumors
- Stage Information for CNS Embryonal Tumors
- Treatment Option Overview for CNS Embryonal Tumors
- Treatment of Newly Diagnosed Childhood Medulloblastoma
- Treatment of Newly Diagnosed Nonmedulloblastoma Embryonal Tumors
- Treatment of Newly Diagnosed Embryonal Tumor With Multilayered Rosettes (Medulloepithelioma)
- Treatment of Newly Diagnosed Pineoblastoma
- Treatment of Recurrent Childhood CNS Embryonal Tumors
- Changes to This Summary (08/02/2017)
- About This PDQ Summary
- View All Sections
Changes to This Summary (08/02/2017)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that a molecularly distinct entity, embryonal tumor with multilayered rosettes (ETMR), C19MC-altered, has been added to the World Health Organization classification, encompassing embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma.
Revised text to state that since 2012, the general consensus is that medulloblastoma can be molecularly separated into at least four core subtypes and within different regions of the same tumor. However, different regions of the same tumor are likely to have other disparate genetic mutations, adding to the complexity of devising effective molecularly targeted therapy (cited Morrissy et al. as reference 23).
Revised text to state that studies show that approximately 50% to 70% of patients with high-risk disease will experience long-term disease control, including those with metastatic disease (cited von Bueren et al. as reference 38 and level of evidence 2A).
Added text to state that in a retrospective multivariate analysis of 38 patients, total or near-total resection, the use of radiation therapy, and the use of high-dose chemotherapy were associated with an improved prognosis (cited Horwitz et al. as reference 4 and level of evidence 3iA).
Added Treatment Options Under Clinical Evaluation as a new subsection.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario